Universal reference book for medicines
Product name: CELLEX ® (CELLEX)

Active substance: nonappropriate

Type: Nootropic preparation

Manufacturer: FARM-SYNTHESIS (Russia) produced DEKO Company (Russia)
Composition, form of production and packaging
Solution for s / c introduction
transparent, colorless or light yellow, odorless or with a specific odor;
opalescence is allowed; it is allowed to have separate strands of coagulum.
1 ml

cellex ® substance-solution (frozen, in terms of protein *) 0.1 mg

Excipients: glycine - 3.75 mg, sodium hydrogen phosphate dihydrate - 2.99 mg, sodium dihydrogen phosphate monohydrate - 0.47 mg, sodium chloride - 5.85 mg, water d / and - up to 1 ml.

* Composition per 1 ml.

Active substance: polypeptides from the brain of porcine embryos active substance in terms of total protein 0.9-2.4 mg (nominal total protein content: 1.65 mg per 1 ml of substance).

Excipients: glycine - 3.75 mg, 0.1 M solution of disodium hydrogen phosphate - up to pH 7.8 (about 0.8 mg of dry matter), sodium chloride - 5.85 mg, polysorbate 80 - 0.005 mg, purified water - up to 1 ml.

1 ml - ampoules of dark glass (1) complete with sterile syringe filter - packings of cellular outlines from polyvinylchloride film (1) - packs of cardboard.

1 ml - ampoules of dark glass (1) complete with a sterile syringe filter - packings of cellular outlines from polyvinylchloride film (2) - packs of cardboard.

1 ml - ampoules of dark glass (2) complete with a sterile syringe filter - packings of cellular outlines from polyvinylchloride film (1) - packs of cardboard.

1 ml - ampoules of dark glass (2) complete with a sterile syringe filter - packings of cellular outlines from polyvinylchloride film (2) - packs of cardboard.

1 ml - ampoules of dark glass (5) complete with sterile syringe filter - packings of cellular outlines from polyvinylchloride film (1) - packs of cardboard.

1 ml - ampoules of dark glass (5) complete with a sterile syringe filter - packings of cellular outlines from polyvinylchloride film (2) - packs of cardboard.

2 ml - dark glass ampoules (1) complete with a sterile syringe filter - packings of cellular outlines from polyvinylchloride film (1) - packs of cardboard.

2 ml - dark glass ampoules (1) complete with a sterile syringe filter - packings of cellular outlines from polyvinylchloride film (2) - packs of cardboard.

2 ml - ampoules of dark glass (2) complete with sterile syringe filter - packings of cellular outlines from polyvinylchloride film (1) - packs of cardboard.

2 ml - ampoules of dark glass (2) complete with sterile syringe filter - packings of cellular outlines from polyvinylchloride film (2) - packs of cardboard.

2 ml - ampoules of dark glass (5) complete with sterile syringe filter - packings of cellular outlines from polyvinylchloride film (1) - packs of cardboard.

2 ml - dark glass ampoules (5) complete with a sterile syringe filter - packings of cellular outlines from a polyvinylchloride film (2) - packs of cardboard.

INSTRUCTION FOR THE SPECIALIST.

Description of the drug approved by the manufacturer for the printed edition of 2016.

PHARMACHOLOGIC EFFECT

The presence of tissue-specific signal proteins and polypeptides - growth factors, nerve cell differentiation factors in the preparation causes its direct neuroreparative effect, due to the regulation of pool concentrations of neurotransmitters, with inhibition of the spilover of excitatory amino acids.

The drug activates secondary neuroprotection due to stimulation of synaptogenesis processes, restoration of autophagy signals, improvement of tissue immunoregulation with inhibition of immunogenic cytotoxicity of macrophages.
In this case, the tissue-specific and systemic reparative effect of the drug is noted with the restoration of the regenerative and reparative potential of brain cells, the reduction in the number of damaged cells and the severity of perifocal edema in the penumbra region (allows a significant restriction of the necrosis of the brain tissue) with restoration of microcirculation and general perfusion.
Restoration and regulatory stimulation of various compartments of the central nervous system with systemic effects of growth factors, differentiation and signaling molecules ensure a reduction in the recovery and rehabilitation of patients with damage to the central and peripheral nervous system of vascular genesis and restoration of motor, sensory and cognitive functions.

The therapeutic effect usually develops 3-5 days after the start of the drug administration.

PHARMACOKINETICS

The complex composition of the preparation Zelleks ® , the active fraction of which consists of a balanced and stable mixture of biologically active proteins and polypeptides having a total polyfunctional action, does not allow the usual pharmacokinetic analysis of individual components.

INDICATIONS

Cerebrovascular diseases:

- acute disorders of cerebral circulation in the acute and early rehabilitation period of the course of the disease as part of complex therapy.

DOSING MODE

For adults, the drug is prescribed in a dose of 0.1-0.2 mg once a day for 10 days, depending on the severity of the patient's condition.
If necessary, repeat the course in 10 days. Studies on the use of the drug in children's practice have not been conducted.
Rules for administering the solution

The drug is injected via a sterile syringe filter included in the kit.

For the administration, the necessary amount of Zelleks ® is poured into the syringe, the needle is removed, then a sterile sterile syringe filter with a pore diameter of 0.22 μm is put on the syringe.
Take a new needle and put it on a sterile syringe filter. The drug is ready for use.
SIDE EFFECT

There may be allergic reactions in the form of unexpressed hyperemia at the injection site, a hypersensitivity reaction (skin rash, itching, angioedema), subfebrile condition, sleep disturbance, headache.

CONTRAINDICATIONS

- epilepsy;

- manic psychosis;

- productive delirium;

- delirium;

- age to 18 years (due to lack of clinical data).

PREGNANCY AND LACTATION

The absence of appropriate studies does not allow the use of the drug in this contingent of patients.

APPLICATION FOR CHILDREN

Contraindicated use of the drug for children and adolescents under the age of 18 years.

SPECIAL INSTRUCTIONS

With special care is prescribed for arterial hypertension malignant course in the stage of decompensation;
sympathetic adrenal crises by the type of panic attacks;expressed anxiety-depressive disorders.
During pregnancy, the effect of the drug has not been studied.

The drug does not contain prion infections and viruses.

Precautions for use

It should be cautious to prescribe the drug in the presence of an anamnesis of allergic reactions to preparations of protein-peptide nature.

Impact on the ability to drive vehicles and manage mechanisms

Currently, there is no evidence of the effect of Zelleks ® on the ability to drive and work with mechanisms that require increased attention and speed of mental and motor reactions.

OVERDOSE

Currently, there have been no cases of overdose of Cellex ® .

DRUG INTERACTION

When combined with psychostimulating drugs and alcohol, psychomotor agitation, sleep disturbances are possible.

Possible a decrease in the activity of funds for anesthesia, tranquilizers, neuroleptics.

TERMS OF RELEASE FROM PHARMACY

The drug is released by prescription.

TERMS AND CONDITIONS OF STORAGE

The drug should be stored in a place protected from light and inaccessible to children, at a temperature of 2 ° to 8 ° C.
Shelf life - 1 year.
Do not apply at the expiration date indicated on the package.

Alphabetical index of medicines:
A  B  V  G  D  E  J
Z  I  Y  K  L  M  N
O  P  R  S  T  U  F
H  C  CH  SH  E  U  Y
Rambler's Top100
Privacy policy:
Copyright 2009 - 2017. Universal reference book of medicines. All rights reserved.
When using site materials, an active hyperlink is required!